Publication at First Faculty of Medicine |
2013
Abstract
Review article deals with castrate-resistant prostate cancer and new treatment options at this stage before chemotherapy. The individual chapters comment on the indications for chemotherapy in the year 2013, the availability of chemotherapy according to the findings from population registries, the possibility of abiraterone or enzalutamide administration in pre-chemotherapy setting and the latest results of studies with new drugs (tasquinimod, cabozantinib, ARN-509, ODM-201 and others).